RTL therapy for multiple sclerosis: a Phase I clinical study. Offner H, Sinha S, Burrows GG, Ferro AJ, Vandenbark AA J Neuroimmunol. 2011 Feb; 231(1-2):7-14. Epub 2010 Oct 20. PMID: 20965577. Abstract
First NW patient to receive OHSU/VAMC-invented MS drug Oregon Health Sciences University, 21 May 2007 Accessed on 19 Dec 2011 from http://www.ohsu.edu/ohsuedu/newspub/052107ms.cfm.
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial Artielle ImmunoTherapeutics, 14 Sep 2009 Accessed on 20 Dec 2011 from http://www.artielle.com/news-and-publications/press-2009-09-14.php.
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects with Multiple Sclerosis ClinicalTrials.gov, 19 Dec 2009 Accessed on 19 Dec 2011 from http://clinicaltrials.gov/ct2/show/NCT00411723.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators Lancet Neurol. 2008 Sep; 7(9):796-804. PMID: 18703004. Abstract
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Offner H, Sinha S, Wang C, Burrows GG, Vandenbark AA Rev Neurosci. 2008; 19(4-5):327-39. PMID: 19145988. Abstract
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2. Chang JW, Mechling DE, Bächinger HP, Burrows GG J Biol Chem. 2001 Jun 29; 276(26):24170-6. Epub 2001 Apr 23. PMID: 11319230. Abstract
Characterization of human platelet binding of recombinant T cell receptor ligand. Itakura A, Aslan JE, Sinha S, White-Adams TC, Patel IA, Meza-Romero R, Vandenbark AA, Burrows GG, Offner H, McCarty O J J Neuroinflammation. 2010; 7:75. Epub 2010 Nov 08. PMID: 21059245. Abstract
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. Sinha S, Miller L, Subramanian S, McCarty O J, Proctor T, Meza-Romero R, Huan J, Burrows GG, Vandenbark AA, Offner H J Neuroimmunol. 2010 Aug 25; 225(1-2):52-61. Epub 2010 May 23. PMID: 20546940. Abstract
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. Sinha S, Subramanian S, Miller L, Proctor TM, Roberts C, Burrows GG, Vandenbark AA, Offner H J Neurosci. 2009 Mar 25; 29(12):3816-23. PMID: 19321778. Abstract
Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. Akiyoshi K, Dziennis S, Palmateer J, Ren X, Vandenbark AA, Offner H, Herson PS, Hurn PD Transl Stroke Res. 2011 Sep 1; 2(3):404-410. PMID: 21961027. Abstract
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis. Adamus G, Karren LJ, Mooney J, Burrows GG Ophthalmic Res. 2010; 44(1):24-33. Epub 2010 Feb 08. PMID: 20145422. Abstract
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice. Adamus G, Brown L, Andrew S, Meza-Romero R, Burrows GG, Vandenbark AA Invest Ophthalmol Vis Sci. 2012 Jan; 53(1):406-12. PMID: 22167100. Abstract
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Meza-Romero R, Benedek G, Leng L, Bucala R, Vandenbark AA Metab Brain Dis. 2016 Feb 6. PMID: 26851955. Abstract